CEO Timothy Warbington.. Contrary to many conventional biotechnology firms that may rely on the sale of intellectual property and patents as a financial exit strategy only after many years of clinical trials and subject to FDA approval, Creative Medical’s multifaceted business model, specific acquisitions and product development are intended to create a cash flow which shall provide an attractive return to its shareholders and provide the resources for expansion, acquisitions and development of cutting edge technology in the areas of stem cell technology and nutraceuticals.
News 
Market Data 
Discover 
